PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.83%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-4.74%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-11.58%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-25.27%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-11.81%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-11.81%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-11.81%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
44.88%
10Y CAGR of 44.88% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that can compound over very long horizons.
-7.45%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
38.84%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 9.25%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
194.01%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 33.56% over a decade. Joel Greenblatt might see a standout compounder of earnings.
16.46%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 1.31%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
59.57%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 0.11%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
131.98%
Equity/share CAGR of 131.98% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
27.65%
5Y equity/share CAGR of 27.65% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
68.35%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 5.47%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
-30.00%
Dividend reductions while Medical - Pharmaceuticals median grows. Seth Klarman sees a near-term disadvantage if peers maintain or raise payouts.
-12.20%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
6.37%
Inventory growth of 6.37% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
1.87%
Asset growth of 1.87% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
5.11%
BV/share growth of 5.11% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-6.73%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
2.77%
SG&A growth far above Medical - Pharmaceuticals median. Jim Chanos sees potential red flags in cost management or diminishing returns on spending.